Federal Byetta, Victoza, Januvia Lawsuits Could See Consolidation This Month, Rottenstein Law Group LLP Reports

USA - English

• USA - English

(PRWEB) July 10, 2013 -- On July 25 a judicial panel will consider the consolidation of federal Byetta, Januvia and Victoza lawsuits for pretrial purposes, according to court documents in In RE: Incretin Mimetics Products Liability Litigation (MDL-2452; U.S. Judicial Panel on Multidistrict Litigation). The Rottenstein Law Group LLP, a law firm that represents clients in Byetta, Victoza and Januvia lawsuits, explains the importance of this decision.

The three drugs each are designed to treat type-2 diabetes. The plaintiffs in the cases for the drugs all have common cause for suit, alleging that they suffered the same potentially dangerous side effects, according to court documents.

A March 2013 announcement* by the U.S. Food and Drug Administration mentioned findings similar to the allegations of the plaintiffs: That the drugs caused inflammation of the pancreas and pre-cancerous changes to the cells of the pancreas. Bristol-Myers Squibb subsidiary Amylin Pharmaceuticals makes Byetta, Merck Januvia and Novo Nordisk Victoza. Byetta and Januvia were also found to potentially increase the risk of thyroid cancer, according to the FDA, though the drugs’ labels did not notify patients of this alleged adverse side effect.**

“A multidistrict consolidation of the lawsuits involving the three drugs would benefit the plaintiffs because it could potentially improve efficiency in time-consuming, costly proceedings such as discovery,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “It reduces, or even eliminates, duplication of efforts.”

The Rottenstein Law Group LLP encourages those who believe they have suffered from the alleged adverse side effects of Byetta, Januvia and Victoza to visit its FAQ page for quick answers to their questions about the drugs, their side effects and lawsuits. If there are additional questions, those looking for more information can use the contact form to get in touch with an attorney.

*fda.gov/Drugs/DrugSafety/ucm343187.htm
**fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190406.htm

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
###

Rochelle Rottenstein, Esq., The Rottenstein Law Group, LLP, http://www.rotlaw.com, (212) 933-9500, [email protected]